Amneal Pharmaceuticals (AMRX) and Metsera said Tuesday that they have signed a collaboration agreement for the development and large-scale supply of new weight-loss medicines globally.

The collaboration will make Amneal Metsera's preferred supply partner in developed markets such as the US and Europe, the partners said.

The partners also said Amneal will be granted a license to commercialize Metsera's products in select emerging markets, such as India.

The collaboration requires Amneal to build two new greenfield manufacturing facilities in India. The facility for peptide synthesis and the sterile fill-finish manufacturing facility will be housed on the same site, and the project is expected to cost $150 million to $200 million over the next four to five years, the partners said. Amneal expects to break ground on the new site later this year.